Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 136   

Articles published

NVO 55.73 -0.43 (-0.77%)
price chart
Novo Nordisk A/S (ADR) 0.4% Potential Upside Indicated yesterday by Leerink ...
Novo Nordisk A/S (ADR) using SYMBOL/TICKER code NYSE:NVO had its stock rating noted as 'Initiated' with the recommendation being set at 'MKT PERFORM' yesterday by analysts at Leerink Partners.
Healthcare Stock's Trend Analysis Report: Novo Nordisk A/S (NVO), CVS ...  Techsonian (press release)
Novo Nordisk A/S (ADR) (NYSE:NVO) on Watch List
[The Motley Fool] Novo Nordisk A/S (ADR) (NYSE:NVO)(TREND ANALYSIS) Diabetes powerhouse Novo Nordisk A/S (ADR) (NYSE:NVO) recently presented impressive data on its type 2 diabetes drug candidate IDegLira. IDegLira is an investigational ...
The winners of healthcare stocks for 2015 : Novo Nordisk A/S (ADR) (NYSE:NVO ...  Wall Street Observer
Novo Nordisk Up on Positive Results from Diabetes Study  Zacks.com
Novo Nordisk Rallies; Signs Antibody Development Deal With Genmab
Novo Nordisk A/S (ADR) (NYSE:NVO) stock is trading up today, after the Danish pharmaceutical company Genmab A/S agreed to grant the insulin-maker two commercial licenses for using its DuoBody technology platform.
Novo Nordisk A/S (ADR) Stock Surges On Increased Profit And Sales
Novo Nordisk A/S (ADR) (NYSE:NVO) announced its earnings for the first quarter of 2015 and the financial guidance for the full year 2015, and said that its current chief executive officer, Lars Rebien Sorensen, will remain at the helm of the company ...
Novo Nordisk CFO: U.S. Obesity Market Must Emerge, But It Will Take Time  Benzinga
Novo Nordisk profit rises; raises 2015 outlook  MarketWatch
Novo Nordisk A/S (ADR) (NYSE:NVO) close to 52-week high, short interest surging
Novo Nordisk A/S (ADR) (NYSE:NVO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $56.27, up by 1.22%, with a volume of 1,155,117 shares against an average volume for the last 3 months of 1,713,340.
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) (NYSE:NVO) on Watch
[ZACKS] Novo Nordisk A/S (ADR) (NYSE:NVO)(TREND ANALYSIS) announced new data from a couple of studies on its approved products, Xultophy and Victoza, during the weekend.
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Hot Stocks on the Run: Alibaba Group Holding Ltd (NYSE:BABA), Novo Nordisk A ...  wsnewspublishers
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.